Ishikawa, Y., Yamauchi, T., Sawa, M., Toubai, T., Najima, Y., Nishida, T., Kawashima, I., Katsuoka, Y., Ozeki, K., Usuki, K., Kiguchi, T., Saito, T., Takada, S., Fujimoto, K., Sato, S., Maeda, T., Yokoyama, H., Uchida, H., Lee, T., Ishida, T., Yamamoto, M., Saito, A., Sakaida, E., Maeda, Y., Matsumura, I., Miyazaki, Y., Kiyoi, H. (2025). A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study. Blood. https://doi.org/10.1182/blood-2025-998